Achieve Life Sciences Reports Q4/FY25 Results, Secures US Manufacturing, & Gains FDA Priority Voucher for Vaping Cessation
Summary
Achieve Life Sciences announced Q4 and full-year 2025 financial results, highlighted by a new US manufacturing partnership for cytisinicline and an FDA Priority Voucher for vaping cessation, alongside progress towards its June 2026 PDUFA date.
Key Events
-
Q4 & Full Year 2025 Financial Results
Reported a net loss of $14.7 million for Q4 2025 and $54.7 million for the full year 2025. Cash, cash equivalents, and marketable securities stood at $36.4 million as of December 31, 2025.
-
US Manufacturing Partnership Secured
Partnered with Adare Pharma Solutions for US-based manufacturing of cytisinicline drug product, aiming to decrease international importation risks, reduce costs, and provide supply chain redundancy.
-
FDA Priority Voucher for Vaping Cessation
Cytisinicline was selected for the inaugural FDA Commissioner's National Priority Voucher for e-cigarette or vaping cessation, which provides enhanced FDA communications and expedited review for this future indication.
-
PDUFA Date Confirmed for Smoking Cessation NDA
Reiterated the Prescription Drug User Fee Act (PDUFA) target action date of June 20, 2026, for the cytisinicline New Drug Application (NDA) for smoking cessation.
Analysis
Achieve Life Sciences reported its fourth quarter and full-year 2025 financial results, showing a net loss of $54.7 million for the year and a cash position of $36.4 million as of December 31, 2025. Beyond the financials, the company announced a significant partnership with Adare Pharma Solutions for US-based manufacturing of cytisinicline, which is expected to decrease supply chain risks and costs, and addresses prior FDA observations. Furthermore, cytisinicline was selected for the FDA Commissioner's National Priority Voucher for e-cigarette or vaping cessation, signaling enhanced FDA communication and expedited review for a future vaping indication. The company also reiterated its PDUFA target action date of June 20, 2026, for the smoking cessation NDA, and detailed progress on commercial readiness, all of which are crucial steps towards potential market launch in the first half of 2027.
At the time of this filing, ACHV was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $215.6M. The 52-week trading range was $1.84 to $6.03. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.